Norton Daniel J, Amariglio Rebecca, Protas Hillary, Chen Kewei, Aguirre-Acevedo Daniel C, Pulsifer Brendan, Castrillon Gabriel, Tirado Victoria, Munoz Claudia, Tariot Pierre, Langbaum Jessica B, Reiman Eric M, Lopera Francisco, Sperling Reisa A, Quiroz Yakeel T
From Massachusetts General Hospital (D.J.N., R.A., B.P., R.A.S., Y.T.Q.); Harvard Medical School (D.J.N., R.A., R.A.S., Y.T.Q.); Center for Alzheimer Research and Treatment, Brigham and Women's Hospital (R.A., R.A.S.), Boston, MA; Banner Alzheimer's Institute (H.P., K.C., P.T., J.B.L., E.M.R.), Phoenix, AZ; Grupo de Neurociencias (D.C.A.-A., V.T., C.M., F.L., Y.T.Q.), Universidad de Antioquia; Instituto de Alta Tecnologia Medica (G.C.), Medellin, Colombia; and Athinoula A Martinos Center for Biomedical Imaging (Y.T.Q.), Boston, MA.
Neurology. 2017 Oct 3;89(14):1464-1470. doi: 10.1212/WNL.0000000000004533. Epub 2017 Sep 6.
To cross-sectionally study subjective memory complaints (SMC) in autosomal dominant Alzheimer disease (ADAD).
We examined self-reported and study partner-based SMC in 52 young, cognitively unimpaired individuals from a Colombian kindred with early-onset ADAD. Twenty-six carried the E280A mutation, averaging 7 years of age younger than the kindred's expected clinical onset. Twenty-six were age-matched noncarriers. Participants also underwent structural MRI and cognitive testing.
Self-reported SMC were greater in carriers than noncarriers ( = 0.02). Study partner-based SMC did not differ between groups ( = 0.21), but in carriers increased with age ( = 0.66, < 0.001) and decreased with hippocampal volume ( = -0.35, = 0.08).
Cognitively unimpaired carriers have elevated SMC. Self-reported SMC may be a relatively early indicator of preclinical AD, while partner- reported SMC increases later in preclinical AD, closer to clinical onset.
对常染色体显性阿尔茨海默病（ADAD）患者的主观记忆障碍（SMC）进行横断面研究。
我们对来自哥伦比亚早发性ADAD家族的52名年轻、认知功能未受损个体进行了自我报告和基于研究伙伴报告的SMC检查。其中26名携带E280A突变，平均年龄比家族预期临床发病年龄小7岁。26名是年龄匹配的非携带者。参与者还接受了结构磁共振成像和认知测试。
携带者自我报告的SMC高于非携带者（P = 0.02）。基于研究伙伴报告的SMC在两组之间无差异（P = 0.21），但在携带者中随年龄增加而增加（P = 0.66，P < 0.001），并随海马体积减小而降低（P = -0.35，P = 0.08）。
认知功能未受损的携带者有较高的SMC。自我报告的SMC可能是临床前AD的一个相对早期指标，而伙伴报告的SMC在临床前AD后期增加，更接近临床发病。
